Overview
- 6 inspections across 6 sites are on record.
- 7 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-06-28.
At a glance
Inspections
6
Sites
6
Observations
7
Career since
May 2013
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Apotex Inc. | 28 Jun 2019 | Human Drugs | |
| Apotex Inc. | 19 Jun 2019 | Human Drugs | |
| AbbVie Inc. | 16 Feb 2018 | Human Drugs | |
| King Pharmaceuticals LLC | 21 Nov 2016 | Human Drugs | View 483 → |
| Element Materials Technology Ann Arbor, LLC | 28 Jun 2016 | Human Drugs |
Sites inspected
Apotex Inc.Richmond Hill, Canada1 insp.
Apotex Inc.North York, Canada1 insp.
AbbVie Inc.Wyandotte, United States1 insp.
King Pharmaceuticals LLCRochester, United States1 insp.
Element Materials Technology Ann Arbor, LLCAnn Arbor, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Emily J Orban3 shared
Truong X Nguyen2 shared
Maria C Iuga1 shared
Bei Y He1 shared
Shirshendu K Deb1 shared
Emilie Kahn1 shared
Sarah M Meng1 shared
Andrew J Idzior1 shared
Full investigator report
Get the verbatim findings behind Aurora-Miha Trifanov's 7 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site